News

  1. Home
  2. News
Full list News Development Recruitment Media Links
2026-05-20
Vitae Biomedical Expands Global Engagement Through WHA Geneva Showcase of Non-Invasive Lung Cancer Risk Assessment

Through participation in WHA-related events in Geneva, Vitae Biomedical showcased its non-invasive urine-based lung cancer testing platform and engaged with international healthcare stakeholders. The event reinforced the growing global interest in accessible cancer risk assessment, clinical follow-up, and preventive health management solutions.

More ›
2026-03-16
Vitae Biomedical Secures Indonesian Patent, Strengthening Southeast Asia Market Position

Vitae Biomedical secures an Indonesian patent, linking IP protection with expansion into a high-growth market. This strengthens entry barriers while supporting future deployment in Southeast Asia.

More ›
2026-02-25
Urine-Based Lung Cancer Screening Gains Traction with High Accuracy and Global Potential

A urine-based lung cancer test with ~90% accuracy offers a non-invasive alternative to traditional screening. Designed for accessibility and scalability, it supports early detection, clinical decision-making, and expansion into global markets.

More ›
2026-01-07
Vitae Biomedical Collaborates with National University of Kaohsiung to Advance Real-Time Urine-Based Cancer Detection

A collaboration with National University of Kaohsiung advances biosensing technology for real-time urine-based cancer detection. By enabling ultra-sensitive and rapid analysis, it supports the next generation of non-invasive diagnostic systems.

More ›
2025-12-26
Vitae Biomedical Recognized with National Innovation Award for Five Consecutive Years

Recognized with the National Innovation Award for five consecutive years, Vitae Biomedical demonstrates consistent R&D progress and execution. This sustained recognition reinforces its credibility in non-invasive diagnostics.

More ›
2025-12-19
Vitae Biomedical Advances Clinical and Channel Integration Through BioLink Collaboration

Vitae Biomedical connects hospitals, pharmacy networks, and home care systems through BioLink collaboration. This integration supports real-world deployment of non-invasive diagnostic solutions.

More ›
2025-12-08
Vitae Biomedical Showcases Innovation at INNOZONE, Expanding Global Visibility and Partnerships

Vitae Biomedical showcases its technology at INNOZONE, attracting global partner interest and reinforcing market demand. This engagement strengthens international visibility and collaboration momentum.

More ›
2025-10-16
Vitae Biomedical Engages Clinical Community and Advances Regulatory Alignment at National Medical Device Forum

Vitae Biomedical engages clinicians and aligns with IVDR regulatory pathways, supporting real-world adoption of its diagnostic platform. This strengthens both clinical trust and global market readiness.

More ›
2025-09-19
Vitae Biomedical Expands Collaboration in Kaunas to Bridge Clinical Validation and Technology Integration

Vitae Biomedical expands collaboration in Lithuania to integrate clinical validation, sensing technology, and innovation resources. This engagement bridges research, product development, and future market deployment.

More ›
2025-09-18
Vitae Biomedical Advances Multi-Ethnic Clinical Validation Through Collaboration in Lithuania

Vitae Biomedical advances cross-population clinical validation through collaboration with leading institutions in Lithuania. By building multi-ethnic evidence, it strengthens global confidence in urine-based cancer detection.

More ›
2025-08-19
Vitae Biomedical Strengthens Japan Market Engagement at Taipei Forum in Osaka

Vitae Biomedical engages Japan’s healthcare ecosystem at the Taipei Forum in Osaka. By exploring clinical and regulatory partnerships, it builds a foundation for future market entry and collaboration.

More ›
2025-08-07
Vitae Biomedical Secures Australian Patent, Strengthening Global IP Position

Vitae Biomedical secures an Australian patent for its core detection technology, marking a shift from filings to granted IP. This strengthens global protection and supports future licensing and market expansion.

More ›
2025-07-24
Vitae Biomedical Advances Non-Invasive Urine Testing for Lung Cancer Detection

A urine-based lung cancer test developed by Vitae Biomedical demonstrates high sensitivity and specificity, both with and without imaging support. Designed to lower screening barriers, the platform expands access to early detection across diverse clinical settings.

More ›
2025-07-17
Vitae Biomedical Advances Non-Invasive Lung Cancer Screening with Urine-Based Detection

A urine-based lung cancer detection platform achieves high sensitivity with and without imaging support. Designed for scalability and global deployment, it expands access to early screening and enables broader clinical adoption.

More ›
2025-04-01
Vitae Biomedical Selected for Two National Programs to Accelerate Quality Systems and Global Market Entry

Selected for two national programs, Vitae Biomedical is advancing quality systems and regulatory readiness in parallel. This dual-track approach accelerates global market entry for its non-invasive diagnostic platform.

More ›
2025-03-03
A Non-Invasive Urine Test for Lung Cancer Risk Detection

A non-invasive urine-based biomarker approach offers a promising way to detect lung cancer risk early. With higher sensitivity than traditional blood markers and no burden on patients, it may serve as a complementary tool alongside imaging for early detection and monitoring.

More ›
2024-10-09
Vitae Biomedical Establishes Market Channels in Japan at Medical Japan Tokyo

Vitae Biomedical establishes initial distribution and healthcare partnerships in Japan at Medical Japan Tokyo. This engagement marks a key step toward market entry and future clinical adoption.

More ›
2024-08-17
Vitae Biomedical Achieves ISO 17025 Certification, Ensuring Laboratory Quality and Data Reliability

Vitae Biomedical achieves ISO 17025 certification, ensuring laboratory quality and data reliability. This strengthens clinical trust and supports global regulatory and partnership readiness.

More ›
2024-07-22
A High-Precision Urine-Based Antigen Test for Lung Cancer Detection

Vitae Biomedical Co., Ltd. is committed to addressing human needs through innovative methods. The company's proprietary antibody technology combined with the Sandwich ELISA method has enabled the development of its flagship product, the "Urine-based Lung Cancer Antigen Detection Kit."

More ›
2024-07-15
Vitae Biomedical Introduces a Urine-Based Platform to Expand Lung Cancer Screening

A urine-based testing platform developed by Vitae Biomedical lowers barriers to lung cancer screening. By supporting nodule management and reducing unnecessary procedures, it expands access to early detection across diverse healthcare settings.

More ›
2024-02-26
Vitae Biomedical Expands Global Patent Portfolio for Lung Cancer Detection Technologies

Vitae Biomedical expands its global patent portfolio across major markets, covering core technologies in antibody design and detection platforms. This strategy strengthens long-term competitiveness in non-invasive cancer diagnostics.

More ›
2022-07-28
Bio Asia-Taiwan 2022 Opening! Vitae Biomedical showcases the new outstanding achievements.

Vitae Biomedical participated in the BIO Asia-Taiwan 2022, targeting people at high risk of lung cancer. The Lung Cancer IVD Reagent shows high accuracy and can help doctors make more effective diagnoses.

More ›
2022-07-14
Keep going, keep climbing! VITAE Biomedical continued moving forward.

VITAE Biomedical entered the National Biotechnology Research Park in 2020, and then accelerated the pace of research and development, successfully developed the prototype of the Lung Cancer urine IVD Reagent, and initiated clinical trials in early 2021.

More ›
2022-06-30
Vitae Biomedical debuts at Bio Asia-Taiwan 2022.

Dr. I-Shu Lee, general manager of Vitae Biomedical, said that the highlights of this exhibition are 1) the EU CE-certified Lung Cancer IVD Reagent, and 2) the medical material class-1 Urine Collection Devices for Lung Cancer IVD certificated by MOHW.

More ›
2022-04-29
VITAE Biomedical High-profile R & D Results Released.

VITAE Biomedical participated in the DEMO DAY of the National Biotechnology Research Park, and published major results that attracted much attention.

More ›
2022-04-28
VITAE Biomedical Deploy in Southern Taiwan.

The investment boom in the Southern Taiwan Science Park has recently reached a total investment of NT$38.9 billion NT dollars. VITAE Biomedical deploy in southern Taiwan, and the factory will be constructed completed this year.

More ›
2020-08-24
Medical Technologist Joins VITAE Biomedical.

In order to establish the highest quality of testing service, VITAE Biomedical has specially hired Medical Technologist to make the VITAE testing service team more complete.

More ›
2020-02-17
The Manufacturing Process of VITAE Lung Cancer Antibody Successfully launched.

The monoclonal antibodies specific for Lung cancer molecular biomarker developed by VITAE Biomedical recently can be produced in small batches (in mg).

More ›
2026-05-20
Vitae Biomedical Expands Global Engagement Through WHA Geneva Showcase of Non-Invasive Lung Cancer Risk Assessment

Through participation in WHA-related events in Geneva, Vitae Biomedical showcased its non-invasive urine-based lung cancer testing platform and engaged with international healthcare stakeholders. The event reinforced the growing global interest in accessible cancer risk assessment, clinical follow-up, and preventive health management solutions.

More ›
2026-03-16
Vitae Biomedical Secures Indonesian Patent, Strengthening Southeast Asia Market Position

Vitae Biomedical secures an Indonesian patent, linking IP protection with expansion into a high-growth market. This strengthens entry barriers while supporting future deployment in Southeast Asia.

More ›
2026-01-07
Vitae Biomedical Collaborates with National University of Kaohsiung to Advance Real-Time Urine-Based Cancer Detection

A collaboration with National University of Kaohsiung advances biosensing technology for real-time urine-based cancer detection. By enabling ultra-sensitive and rapid analysis, it supports the next generation of non-invasive diagnostic systems.

More ›
2025-12-26
Vitae Biomedical Recognized with National Innovation Award for Five Consecutive Years

Recognized with the National Innovation Award for five consecutive years, Vitae Biomedical demonstrates consistent R&D progress and execution. This sustained recognition reinforces its credibility in non-invasive diagnostics.

More ›
2025-12-19
Vitae Biomedical Advances Clinical and Channel Integration Through BioLink Collaboration

Vitae Biomedical connects hospitals, pharmacy networks, and home care systems through BioLink collaboration. This integration supports real-world deployment of non-invasive diagnostic solutions.

More ›
2025-12-08
Vitae Biomedical Showcases Innovation at INNOZONE, Expanding Global Visibility and Partnerships

Vitae Biomedical showcases its technology at INNOZONE, attracting global partner interest and reinforcing market demand. This engagement strengthens international visibility and collaboration momentum.

More ›
2025-10-16
Vitae Biomedical Engages Clinical Community and Advances Regulatory Alignment at National Medical Device Forum

Vitae Biomedical engages clinicians and aligns with IVDR regulatory pathways, supporting real-world adoption of its diagnostic platform. This strengthens both clinical trust and global market readiness.

More ›
2025-09-19
Vitae Biomedical Expands Collaboration in Kaunas to Bridge Clinical Validation and Technology Integration

Vitae Biomedical expands collaboration in Lithuania to integrate clinical validation, sensing technology, and innovation resources. This engagement bridges research, product development, and future market deployment.

More ›
2025-09-18
Vitae Biomedical Advances Multi-Ethnic Clinical Validation Through Collaboration in Lithuania

Vitae Biomedical advances cross-population clinical validation through collaboration with leading institutions in Lithuania. By building multi-ethnic evidence, it strengthens global confidence in urine-based cancer detection.

More ›
2025-08-19
Vitae Biomedical Strengthens Japan Market Engagement at Taipei Forum in Osaka

Vitae Biomedical engages Japan’s healthcare ecosystem at the Taipei Forum in Osaka. By exploring clinical and regulatory partnerships, it builds a foundation for future market entry and collaboration.

More ›
2025-08-07
Vitae Biomedical Secures Australian Patent, Strengthening Global IP Position

Vitae Biomedical secures an Australian patent for its core detection technology, marking a shift from filings to granted IP. This strengthens global protection and supports future licensing and market expansion.

More ›
2025-04-01
Vitae Biomedical Selected for Two National Programs to Accelerate Quality Systems and Global Market Entry

Selected for two national programs, Vitae Biomedical is advancing quality systems and regulatory readiness in parallel. This dual-track approach accelerates global market entry for its non-invasive diagnostic platform.

More ›
2024-10-09
Vitae Biomedical Establishes Market Channels in Japan at Medical Japan Tokyo

Vitae Biomedical establishes initial distribution and healthcare partnerships in Japan at Medical Japan Tokyo. This engagement marks a key step toward market entry and future clinical adoption.

More ›
2024-08-17
Vitae Biomedical Achieves ISO 17025 Certification, Ensuring Laboratory Quality and Data Reliability

Vitae Biomedical achieves ISO 17025 certification, ensuring laboratory quality and data reliability. This strengthens clinical trust and supports global regulatory and partnership readiness.

More ›
2024-02-26
Vitae Biomedical Expands Global Patent Portfolio for Lung Cancer Detection Technologies

Vitae Biomedical expands its global patent portfolio across major markets, covering core technologies in antibody design and detection platforms. This strategy strengthens long-term competitiveness in non-invasive cancer diagnostics.

More ›
2022-04-29
VITAE Biomedical High-profile R & D Results Released.

VITAE Biomedical participated in the DEMO DAY of the National Biotechnology Research Park, and published major results that attracted much attention.

More ›
2020-02-17
The Manufacturing Process of VITAE Lung Cancer Antibody Successfully launched.

The monoclonal antibodies specific for Lung cancer molecular biomarker developed by VITAE Biomedical recently can be produced in small batches (in mg).

More ›
2020-08-24
Medical Technologist Joins VITAE Biomedical.

In order to establish the highest quality of testing service, VITAE Biomedical has specially hired Medical Technologist to make the VITAE testing service team more complete.

More ›
2026-02-25
Urine-Based Lung Cancer Screening Gains Traction with High Accuracy and Global Potential

A urine-based lung cancer test with ~90% accuracy offers a non-invasive alternative to traditional screening. Designed for accessibility and scalability, it supports early detection, clinical decision-making, and expansion into global markets.

More ›
2025-07-24
Vitae Biomedical Advances Non-Invasive Urine Testing for Lung Cancer Detection

A urine-based lung cancer test developed by Vitae Biomedical demonstrates high sensitivity and specificity, both with and without imaging support. Designed to lower screening barriers, the platform expands access to early detection across diverse clinical settings.

More ›
2025-07-17
Vitae Biomedical Advances Non-Invasive Lung Cancer Screening with Urine-Based Detection

A urine-based lung cancer detection platform achieves high sensitivity with and without imaging support. Designed for scalability and global deployment, it expands access to early screening and enables broader clinical adoption.

More ›
2025-03-03
A Non-Invasive Urine Test for Lung Cancer Risk Detection

A non-invasive urine-based biomarker approach offers a promising way to detect lung cancer risk early. With higher sensitivity than traditional blood markers and no burden on patients, it may serve as a complementary tool alongside imaging for early detection and monitoring.

More ›
2024-07-22
A High-Precision Urine-Based Antigen Test for Lung Cancer Detection

Vitae Biomedical Co., Ltd. is committed to addressing human needs through innovative methods. The company's proprietary antibody technology combined with the Sandwich ELISA method has enabled the development of its flagship product, the "Urine-based Lung Cancer Antigen Detection Kit."

More ›
2024-07-15
Vitae Biomedical Introduces a Urine-Based Platform to Expand Lung Cancer Screening

A urine-based testing platform developed by Vitae Biomedical lowers barriers to lung cancer screening. By supporting nodule management and reducing unnecessary procedures, it expands access to early detection across diverse healthcare settings.

More ›
2022-07-28
Bio Asia-Taiwan 2022 Opening! Vitae Biomedical showcases the new outstanding achievements.

Vitae Biomedical participated in the BIO Asia-Taiwan 2022, targeting people at high risk of lung cancer. The Lung Cancer IVD Reagent shows high accuracy and can help doctors make more effective diagnoses.

More ›
2022-07-14
Keep going, keep climbing! VITAE Biomedical continued moving forward.

VITAE Biomedical entered the National Biotechnology Research Park in 2020, and then accelerated the pace of research and development, successfully developed the prototype of the Lung Cancer urine IVD Reagent, and initiated clinical trials in early 2021.

More ›
2022-06-30
Vitae Biomedical debuts at Bio Asia-Taiwan 2022.

Dr. I-Shu Lee, general manager of Vitae Biomedical, said that the highlights of this exhibition are 1) the EU CE-certified Lung Cancer IVD Reagent, and 2) the medical material class-1 Urine Collection Devices for Lung Cancer IVD certificated by MOHW.

More ›
2022-04-28
VITAE Biomedical Deploy in Southern Taiwan.

The investment boom in the Southern Taiwan Science Park has recently reached a total investment of NT$38.9 billion NT dollars. VITAE Biomedical deploy in southern Taiwan, and the factory will be constructed completed this year.

More ›
Research Establishment

National Health Research Institutes

Link

National Biotechnology Research Park

Link

Academia Sinica

Link
Consultant Establishment

Medical and Pharmaceutical Industry Technology and Development Center.

Link

Development Center for Biotechnology

Link
Certification Establishment

Center For Drug Evaluation

Link

Taiwan Accreditation Foundation

Link

Food and Drug Administration

Link
  • Addr.：WR03, 17F, No.3, Park St., Nangang District, Taipei 115, Taiwan, R.O.C.
  • TEL:+886-2-2697-6509

Copyright © 2020 VITAE Biomedical Co., Ltd. All Rights Reserved